Legacy Pharma Drug Patent Portfolio
Legacy Pharma owns 3 orange book drugs protected by 13 US patents Given below is the list of Legacy Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166205 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10166206 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10695303 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10729667 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US8778365 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US9161914 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US8658663 | Method of treating thermoregulatory disfunction with paroxetine | 06 Apr, 2029 | Active |
| US8946251 | Method of treating thermoregulatory dysfunction with paroxetine | 04 Aug, 2026 | Active |
| US9393237 | Method of treating thermoregulatory dysfunction with paroxetine | 04 Aug, 2026 | Active |
| US7598271 | Crystalline paroxetine methane sulfonate | 04 May, 2025 | Active |
| US6284770 | Medicaments for the treatment of non-constipated female irritable bowel syndrome | 05 Oct, 2018 | Expired |
| US5874447 | 4-Phenylpiperidine compounds for treating depression | 10 Jun, 2017 | Expired |
| US5360800 | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | 13 Jan, 2013 | Expired |
Latest Legal Activities on Legacy Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Legacy Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 Jan, 2024 | US10729667 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 03 Jan, 2024 | US9393237 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Dec, 2023 | US10695303 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Apr, 2023 | US9161914 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 20 Jul, 2022 | US8946251 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166205 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166206 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 29 Dec, 2021 | US8778365 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 11 Aug, 2021 | US8658663 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 Jul, 2021 | US10729667 |
|
Email Notification
Critical
| 06 Jul, 2021 | US10729667 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US10166205 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US8658663 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US10166206 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US9393237 |
Legacy Pharma's Drug Patent Litigations
Legacy Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 30, 2012, against patent number US8658663. The petitioner , challenged the validity of this patent, with Patricia Allison Tewes Richards as the respondent. Click below to track the latest information on how companies are challenging Legacy Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8658663 | January, 2012 |
Decision
(21 Oct, 2013)
| Patricia Allison Tewes Richards | |
Legacy Pharma's Family Patents
Legacy Pharma Drug List
Given below is the complete list of Legacy Pharma's drugs and the patents protecting them.
1. Brisdelle
Brisdelle is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8658663 | Method of treating thermoregulatory disfunction with paroxetine |
06 Apr, 2029
(4 years from now)
| Active |
| US8946251 | Method of treating thermoregulatory dysfunction with paroxetine |
04 Aug, 2026
(1 year, 5 months from now)
| Active |
| US9393237 | Method of treating thermoregulatory dysfunction with paroxetine |
04 Aug, 2026
(1 year, 5 months from now)
| Active |
| US7598271 | Crystalline paroxetine methane sulfonate |
04 May, 2025
(2 months from now)
| Active |
| US5874447 | 4-Phenylpiperidine compounds for treating depression |
10 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brisdelle's drug page
2. Lotronex
Lotronex is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6284770 | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
05 Oct, 2018
(6 years ago)
| Expired |
| US5360800 | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
13 Jan, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotronex's drug page
3. Naftin
Naftin is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166205 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US10166206 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US10695303 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US10729667 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US8778365 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US9161914 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naftin's drug page